Researchers have identified a new biomarker to predict treatment response for myelodysplastic syndromes (MDS), specifically two groupings of hematopoietic stem cells that can predict response to treatment with venetoclax-based therapy.
“This research advocates that the stem cell profile of MDS should be considered to determine appropriate therapeutic approaches targeting these cells, particularly for venetoclax-based therapy,” primary investigator Simona Colla, PhD, an associate